This morning, together with the Capital Region District (CRD) of Vancouver, Waga Energy announced it has completed the commissioning and therefore started to produce biomethane in Hartland (Canada). The site has been equipped with a Wagabox capable of producing approximately 100GWh/year of biometha
This morning, Waga Energy announced a new contract in Rosignano Marittimo (Italy) on a site operated by Scapigliato, a public Italian company active in non-hazardous waste management. Planned to be operational in 2027, this site will be equipped with a Wagabox able to produce more than 92GWh/year o
Following Waga Energy's FY results and taking advantage of the roadshow held recently with management, we have updated our model, reviewing our sales and margin assumptions from 2025 onwards. Waga Energy has a unique landfill gas treatment technology (known as cryogenic distillation), already secur
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 by 4%.Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week mainten...
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, FrancePhase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025 PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage ...
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chr...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.